Measuring glucose uptake in primary invasive breast cancer using simultaneous time-of-flight breast pet/ mri: A method comparison study with prone pet/ct

Abstract

Purpose: To compare the measurement of glucose uptake in primary invasive breast cancer using simultaneous, time-of-flight breast PET/MRI with prone time-of-flight PET/CT. Materials and Methods: In this prospective study, women with biopsy-proven invasive breast cancer undergoing preoperative breast MRI from 2016 to 2018 were eligible. Participants who had fasted underwent prone PET/CT of the breasts approximately 60 minutes after injection of 370 MBq (10 mCi) fluorine 18 fluorodeoxyglucose (18F-FDG) followed by prone PET/MRI using standard clinical breast MRI sequences performed simultaneously with PET acquisition. Volumes of interest were drawn for tumors and contralateral normal breast fibroglandular tissue to calculate standardized uptake values (SUVs). Spearman correlation, Wilcoxon signed ranked test, Mann-Whitney test, and Bland-Altman analyses were performed. Results: Twenty-three women (mean age, 50 years; range, 33–70 years) were included. Correlation between tumor uptake values measured with PET/MRI and PET/CT was strong (rs = 0.95–0.98). No difference existed between modalities for tumor maximum SUV (SUVmax ) normalized to normal breast tissue SUVmean (normSUVmax ) (P = .58). The least amount of measurement bias was observed with normSUVmax, +3.86% (95% limits of agreement: −28.92, +36.64). Conclusion: These results demonstrate measurement agreement between PET/CT, the current reference standard for tumor glucose uptake quantification, and simultaneous time-of-flight breast18F-FDG PET/MRI.